BioSpace News Archive

Acumen Pharmaceuticals, Inc. presented positive topline results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage AβO targeting antibody therapy in early AD, at the Alzheimer’s Association International Conference 2023, taking place in Amsterdam and online from July 16-20, 2023.

The Committee to Restore Nymox Shareholder Value, LLC, with a goal to recover shareholder value in NYMOX PHARMACEUTICAL CORP by reestablishing a proposed partnership with a highly respected, global specialty pharmacy and healthcare solutions company, resolutely refutes all allegations made in a press release by current Nymox leadership.

Two new CRISPR-based therapeutic approaches for Alzheimer’s were reported at the Alzheimer’s Association International Conference® 2023, in Amsterdam, Netherlands, and online.

Antengene Corporation Limited announced that the Department of Health, the Government of the HKSAR has approved a NDA for XPOVIO®.

TauRx Pharmaceuticals Ltd. announced results from a prespecified analysis of the Phase 3 LUCIDITY trial that measured the impact of HMTM on neurofilament light chain, an established biomarker for brain neurodegeneration.